CIK 0001815442 · Large accelerated filer
Kymera Therapeutics, Inc.
Sign in to watch- Ticker
- KYMR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812992166
- Phone
- 857-285-5314
- Business address
- 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA, 02472
- Former names
- Kymera Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,158,214
- in 2 filings, $3.4M under 10b5-1 plans
Net −$4,158,214. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-25 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −19,764 | $89.78 | $1.8M | 676,431 |
| 2026-02-25 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −5,434 | $90.39 | $491K | 670,997 |
| 2026-02-25 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −3,293 | $91.76 | $302K | 667,704 |
| 2026-02-25 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −1,501 | $92.81 | $139K | 666,203 |
| 2026-02-25 | Mainolfi Nello Chief Executive Officer | Sale 10b5-1 | −8 | $93.49 | $748 | 666,195 |
| 2026-02-25 | Mainolfi Nello Chief Executive Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −30,000 | 245,559 | ||
| 2026-02-20 | Esposito Pamela Director | Option exercise 10b5-1 | +2,500 | $49.10 | $123K | 2,500 |
| 2026-02-20 | Esposito Pamela Director | Sale 10b5-1 | −1,900 | $87.06 | $165K | 600 |
| 2026-02-20 | Esposito Pamela Director | Sale 10b5-1 | −600 | $88.10 | $53K | 0 |
| 2026-02-20 | Esposito Pamela Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,500 | 2,500 | ||
| 2026-01-20 | Esposito Pamela Director | Option exercise 10b5-1 | +3,000 | $31.20 | $94K | 3,000 |
| 2026-01-20 | Esposito Pamela Director | Option exercise 10b5-1 | +2,500 | $49.10 | $123K | 5,500 |
| 2026-01-20 | Esposito Pamela Director | Sale 10b5-1 | −400 | $66.68 | $27K | 5,100 |
| 2026-01-20 | Esposito Pamela Director | Sale 10b5-1 | −4,900 | $67.99 | $333K | 200 |
| 2026-01-20 | Esposito Pamela Director | Sale 10b5-1 | −200 | $68.52 | $14K | 0 |
| 2026-01-20 | Esposito Pamela Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,000 | 10,000 | ||
| 2026-01-20 | Esposito Pamela Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −2,500 | 5,000 | ||
| 2026-01-05 | Mainolfi Nello Chief Executive Officer | Option exercise | +3,118 | $32.07 | $100K | 666,195 |
| 2026-01-05 | Mainolfi Nello Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −3,118 | 446,882 | ||
| 2025-12-31 | Mainolfi Nello Chief Executive Officer | Option exercise 10b5-1 | +30,000 | $2.08 | $62K | 693,077 |
Page 17 of 25 · 493 trades